Cardiff Oncology to Participate in Three Upcoming Investor Conferences

Core Insights - Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing novel therapies through PLK1 inhibition for various cancers [3] Group 1: Upcoming Investor Conferences - Cardiff Oncology management will participate in three investor conferences in September 2025 [1] - The conferences include the Wells Fargo 20 Annual Healthcare Conference on September 5, 2025, the Morgan Stanley 23 Annual Global Healthcare Conference on September 8, 2025, and the H.C. Wainwright 27 Annual Global Investment Conference on September 9, 2025 [2] Group 2: Company Overview - The lead asset of Cardiff Oncology is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care therapies for RAS-mutated metastatic colorectal cancer and other cancers [3] - The company's development strategy aims to target tumor vulnerabilities to overcome treatment resistance and provide superior clinical benefits compared to standard therapies [3]